The analytics your life sciences BD&L team could be missing

Whether you’re sizing the addressable market for a specific disease area or refining your pricing assumptions for a potential new asset, you need analytics that can give you the most precise inputs, fast.  We released a new analytics software, called Clarify Portfolio, to help business development and licensing (BD&L) teams make better investment decisions. It arms you with the input needed to gauge the true [...]

2021-01-06T16:42:15-08:00January 6th, 2021|

Pharma commercial leaders talk about decoding patient journeys

This month, Clarify Health hosted a webinar with Reuters Events Pharma to discuss decoding patient journeys for commercial impact. It included an all-star panel of speakers from Clarify, Eli Lilly, and Boehringer Ingelheim, and it was moderated by Reuters. Attendees were primarily from pharmaceutical and biotechnology companies, working in the [...]

2020-12-18T13:49:55-08:00December 18th, 2020|

The traditional pharma commercialization model is outdated

  The revenue performance of a pharmaceutical drug at launch sets the stage for its commercial future. However, approximately two-thirds of new drugs fall short of first-year sales expectations. In this HLTH GoLive series webinar, “Rearchitecting the Drug Launch Model,” Manisha Gulati, Chief Operating Officer, Clarify Health, asked an expert [...]

2020-07-13T17:22:53-08:00July 13th, 2020|